GlassScriptPhysician profile
Paul D Bates
NPI 1518021518
$7,595.21
in general payments reported to CMS, 2019-2025
49 companies · $2,752 in 2025
The $2,752 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $1,134 · 2023: $1,419 · 2024: $2,017 · 2025: $2,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,088 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,088.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,188.87 | 2021-2025 | |
| Abbvie INC. | $1,160.65 | 2021-2025 | |
| Harmony Biosciences LLC | $711.79 | 2021-2025 | Wakix |
| Axsome Therapeutics, INC. | $636.52 | 2023-2025 | Sunosi, Symbravo |
| Avadel Cns Pharmaceuticals, LLC | $548.75 | 2024-2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $306.92 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Ucb, INC. | $264.48 | 2022-2025 | Briviact, Rystiggo, Zilbrysq |
| Inspire Medical Systems, INC. | $249.62 | 2023-2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $227.06 | 2022-2025 | Ultomiris |
| Genzyme Corporation | $191.62 | 2022-2025 | |
| Lilly USA, LLC | $165.11 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Idorsia Pharmaceuticals US INC | $127.92 | 2023 | Quviviq |
| Grifols USA, LLC | $127.41 | 2025 | Prolastin-C Liquid, Gamunex-C |
| Supernus Pharmaceuticals, INC. | $113.42 | 2021-2022 | |
| United Therapeutics Corporation | $111.88 | 2023-2025 | Tyvaso, Tyvaso |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.